InMed Pharmaceuticals (INM) Non-Current Assets (2020 - 2026)

InMed Pharmaceuticals has reported Non-Current Assets for 7 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 21.75% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.9 million (down 18.8% YoY), and the FY2025 full-year result was $2.7 million, down 13.42% from the prior year.
• Non-Current Assets for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $6.7 million in Q1 2022, with the low at $2.2 million in Q1 2026.
• Historically, Non-Current Assets has averaged $3.1 million across 5 years, with a median of $2.9 million in 2022.
• The largest YoY upside for Non-Current Assets was 365.3% in 2022 against a maximum downside of 57.81% in 2022.
• InMed Pharmaceuticals' Non-Current Assets stood at $2.9 million in 2022, then rose by 18.73% to $3.4 million in 2023, then fell by 11.99% to $3.0 million in 2024, then declined by 20.76% to $2.4 million in 2025, then decreased by 6.54% to $2.2 million in 2026.
• The last three Non-Current Assets figures came in at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.